MCID: INT066
MIFTS: 57

Interstitial Lung Disease

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Interstitial Lung Disease

MalaCards integrated aliases for Interstitial Lung Disease:

Name: Interstitial Lung Disease 12 50 14
Lung Diseases, Interstitial 42 69
Lung Diseases Interstitial 52
Interstitial Lung Diseases 41
Ild 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3082
ICD10 33 J84.9
MeSH 42 D017563
SNOMED-CT 64 233703007 64667001
UMLS 69 C0206062

Summaries for Interstitial Lung Disease

NIH Rare Diseases : 50 interstitial lung diseases (ilds) are a large group of disorders characterized by thickening of the walls between the alveoli, increased production and buildup of collagen, and pulmonary fibrosis (progressive scarring of lung tissue). the scarring eventually affects the ability to breathe and get enough oxygen into the bloodstream. symptoms typically include shortness of breath and a dry cough. there are numerous possible causes of ild, including connective tissue disorders, autoimmune diseases (e.g. rheumatoid arthritis), occupational exposures (such as asbestos), infection, and many drugs. specific diseases leading to ild may include sarcoidosis, pulmonary langerhans cell histiocytosis, and eosinophilic pulmonary diseases. the list of substances and conditions that can lead to ild is long. however, in many cases, the cause is not known. some cases of unknown cause that share similar characteristics are called idiopathic interstitial pneumonias. lung scarring that occurs in ild is permanent. however, some treatments may temporarily improve symptoms or slow the disease's progress. treatment options may include various medications, oxygen therapy, pulmonary rehabilitation, and as a last resort, lung transplantation. last updated: 7/31/2017

MalaCards based summary : Interstitial Lung Disease, also known as lung diseases, interstitial, is related to pneumoconiosis and rheumatoid arthritis, and has symptoms including coughing, hemoptysis and snoring. An important gene associated with Interstitial Lung Disease is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are ERK Signaling and Metabolism of proteins. The drugs Bosentan and Daclizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotypes are Decreased viability with paclitaxel and homeostasis/metabolism

MedlinePlus : 41 interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. the inflammation and scarring make it hard to get enough oxygen. the scarring is called pulmonary fibrosis. breathing in dust or other particles in the air is responsible for some types of interstitial lung diseases. specific types include black lung disease among coal miners, from inhaling coal dust farmer's lung, from inhaling farm dust asbestosis, from inhaling asbestos fibers siderosis, from inhaling iron from mines or welding fumes silicosis, from inhaling silica dust other causes include autoimmune diseases or occupational exposures to molds, gases, or fumes. some types of interstitial lung disease have no known cause. treatment depends on the type of exposure and the stage of the disease. it may involve medicines, oxygen therapy, or a lung transplant in severe cases.

Wikipedia : 72 Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of lung diseases... more...

Related Diseases for Interstitial Lung Disease

Diseases related to Interstitial Lung Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 307)
id Related Disease Score Top Affiliating Genes
1 pneumoconiosis 32.2 CCL2 CCL5 CXCL8
2 rheumatoid arthritis 30.2 CCL2 CCL5 CXCL8 IL1A IL1B TGFB1
3 pulmonary tuberculosis 30.0 CCL2 CCL5 CXCL8 TNF
4 atherosclerosis 29.5 CCL2 CXCL8 IL1A IL1B TNF
5 asthma 28.5 CCL17 CCL5 CXCL8 EDN1 IL1A IL1B
6 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.3
7 children's interstitial lung disease 12.3
8 drug or radiation exposure-related interstitial lung disease 11.9
9 respiratory bronchiolitis-interstitial lung disease syndrome 11.9
10 autoimmune interstitial lung, joint, and kidney disease 11.5
11 interstitial pneumonitis, desquamative, familial 11.5
12 antisynthetase syndrome 11.3
13 pulmonary fibrosis 11.3
14 dermatomyositis 11.3
15 extrinsic allergic alveolitis 11.3
16 surfactant dysfunction 11.2
17 surfactant metabolism dysfunction, pulmonary, 2 11.2
18 surfactant metabolism dysfunction, pulmonary, 3 11.2
19 surfactant metabolism dysfunction, pulmonary, 1 11.1
20 lung disease 11.0
21 tracheoesophageal fistula symphalangism 11.0 SFTPB SFTPD
22 pulmonary alveolar microlithiasis 10.9
23 sting-associated vasculopathy, infantile-onset 10.9
24 choreoathetosis, hypothyroidism, and neonatal respiratory distress 10.9
25 pulmonary surfactant metabolism dysfunction 10.9
26 abca3-related pulmonary surfactant metabolism dysfunction 10.9
27 sftpb-related pulmonary surfactant metabolism dysfunction 10.9
28 sftpc-related pulmonary surfactant metabolism dysfunction 10.9
29 coronary stenosis 10.8 SFTPB SFTPC SFTPD
30 smarca4-deficient sarcoma of thorax 10.8 CCL5 TNF
31 cranial nerve malignant neoplasm 10.8 CCL2 SFTPC TGFB1
32 interstitial lung and liver disease 10.8
33 niemann-pick disease, type c2 10.8
34 mucoepithelial dysplasia, hereditary 10.8
35 anthracosis 10.8
36 bagassosis 10.8
37 beryllium disease 10.8
38 cytomegalovirus retinitis 10.8 CCL2 CXCL8
39 bladder diverticulum 10.8 MUC1 SFTPD TNF
40 anonychia with flexural pigmentation 10.7 ABCA3 SFTPB SFTPC
41 anoxia 10.7 ABCA3 SFTPB SFTPC
42 malignant neoplasm of acoustic nerve 10.7 MUC1 SFTPD
43 plantar wart 10.7 CXCL8 TGFB1 TNF
44 toxic optic neuropathy 10.7 IL1A IL1B
45 esophagus leiomyoma 10.7 CXCL8 MUC1 TNF
46 oculomotor nerve paralysis 10.7 CXCL8 IL1B
47 neurotrophic keratoconjunctivitis 10.7 CCL2 SFTPB SFTPC SFTPD
48 liver disease 10.7 IL1A IL1B MUC1
49 tumefactive multiple sclerosis 10.7 CCL2 CXCL8 TNF
50 common peroneal nerve lesion 10.7 CXCL8 IL1B

Graphical network of the top 20 diseases related to Interstitial Lung Disease:



Diseases related to Interstitial Lung Disease

Symptoms & Phenotypes for Interstitial Lung Disease

UMLS symptoms related to Interstitial Lung Disease:


coughing, hemoptysis, snoring

GenomeRNAi Phenotypes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR TGFB1
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR TGFB1

MGI Mouse Phenotypes related to Interstitial Lung Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 TF TGFB1 TNF ABCA3 EDN1 EGFR
2 hematopoietic system MP:0005397 10.11 CCL17 CCL5 EGFR IFIH1 IL1A IL1B
3 cardiovascular system MP:0005385 10.1 ABCA3 EDN1 EGFR IL1A IL1B ITGA3
4 immune system MP:0005387 10.07 EGFR IFIH1 IL1A IL1B ITGA3 MUC5B
5 mortality/aging MP:0010768 10 ABCA3 EDN1 EGFR IFIH1 IL1B ITGA3
6 neoplasm MP:0002006 9.56 EGFR IL1A IL1B ITGA3 NKX2-1 SFTPC
7 respiratory system MP:0005388 9.32 ABCA3 EGFR ITGA3 MUC5B NKX2-1 SFTPB

Drugs & Therapeutics for Interstitial Lung Disease

Drugs for Interstitial Lung Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2,Phase 3 147536-97-8 104865
2
Daclizumab Approved, Investigational Phase 4 152923-56-3
3
Everolimus Approved Phase 4,Phase 3 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 3 53123-88-9 5284616 6436030 46835353
6
Calcium Carbonate Approved Phase 4 471-34-1
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
9
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 3 78919-13-8 6443959
10
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
11
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
12
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-24-8 5755
15
Menthol Approved Phase 4 2216-51-5 16666
16
Gefitinib Approved, Investigational Phase 4,Phase 3 184475-35-2 123631
17
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
18
Morphine Approved, Investigational Phase 4 57-27-2 5288826
19
Ledipasvir Approved Phase 4 1256388-51-8 67505836
20
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
21 Gallopamil Investigational Phase 4 16662-47-8
22
Pirfenidone Investigational Phase 4,Phase 2 53179-13-8 40632
23
Lactitol Investigational Phase 4,Phase 3 585-86-4 3871
24 Antihypertensive Agents Phase 4,Phase 3,Phase 2
25 Endothelin Receptor Antagonists Phase 4,Phase 2,Phase 3
26 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3
27 Phosphodiesterase Inhibitors Phase 4,Phase 3
28 Sildenafil Citrate Phase 4 171599-83-0
29 Vasodilator Agents Phase 4,Phase 2,Phase 3
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
31 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
32 Antifungal Agents Phase 4,Phase 3,Phase 2
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2
35 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
36 Cyclosporins Phase 4,Phase 3,Phase 2
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 4,Phase 2,Phase 3
39 Antacids Phase 4
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Early Phase 1
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
42 Anti-Ulcer Agents Phase 4
43 Calcium, Dietary Phase 4
44 Gastrointestinal Agents Phase 4,Early Phase 1
45 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
49 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
50 Analgesics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 277)

id Name Status NCT ID Phase Drugs
1 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
2 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Unknown status NCT00625079 Phase 4 sildenafil;sildenafil
3 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Unknown status NCT02286063 Phase 4 Ambulatory Oxygen
4 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Unknown status NCT00625469 Phase 4 bosentan
5 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
6 Fibrosis in Renal Allografts Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
7 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
8 Pulmonary Rehabilitation in Interstitial Lung Diseases Completed NCT00882817 Phase 4
9 Iressa Case Control Study in Japan Completed NCT00252759 Phase 4
10 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
11 Novartis Everolimus Transition Completed NCT02096107 Phase 4 Everolimus
12 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep Recruiting NCT02150616 Phase 4 Oxygen;Sham oxygen (room air)
13 Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance Recruiting NCT02143687 Phase 4 Oxygen;Sham oxygen (room air)
14 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride
15 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
16 Hepatitis C Virus(HCV) Heart and Lung Study Recruiting NCT02858180 Phase 4 Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
17 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
18 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Unknown status NCT00705133 Phase 3 treprostinil
19 Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection Unknown status NCT00841750 Phase 3
20 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
21 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
22 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3 Tacrolimus
23 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3 bosentan
24 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
25 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
26 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
27 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
28 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
29 A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy Completed NCT01955824 Phase 2, Phase 3 1% lignocaine;2% lignocaine
30 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
31 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
32 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
33 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients Completed NCT01079143 Phase 3 Certican®;Neoral;Myfortic;Simulect®;Corticosteroids
34 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Recruiting NCT02999178 Phase 3 Nintedanib;Placebo
35 Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease Recruiting NCT01570764 Phase 3 Cyclophosphamide;Placebo
36 Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases Recruiting NCT02990286 Phase 3 Rituximab;Placebo of Rituximab;Mycophenolate Mofetil
37 Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Recruiting NCT02896205 Phase 3 Mycophenolate mofetil;Placebo
38 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
39 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Recruiting NCT02597933 Phase 3 Nintedanib;Placebo
40 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Recruiting NCT02630316 Phase 2, Phase 3 Inhaled Treprostinil;Placebo
41 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC Recruiting NCT02474355 Phase 3 AZD9291 Dosing
42 Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease Recruiting NCT03241420 Phase 3
43 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Active, not recruiting NCT01973998 Phase 3 Roflumilast;Placebo
44 Rituximab in Interstitial Pneumonitis Active, not recruiting NCT02251964 Phase 2, Phase 3 Rituximab
45 An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Enrolling by invitation NCT02633293 Phase 2, Phase 3 Inhaled Treprostinil
46 A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. Not yet recruiting NCT03313180 Phase 3 Nintedanib
47 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
48 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Terminated NCT00768300 Phase 3 Ambrisentan;Placebo
49 Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure Terminated NCT03262571 Phase 3
50 GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases Terminated NCT01257802 Phase 3 depot leuprolide acetate 3.75 mg;Placebo

Search NIH Clinical Center for Interstitial Lung Disease

Cochrane evidence based reviews: lung diseases, interstitial

Genetic Tests for Interstitial Lung Disease

Anatomical Context for Interstitial Lung Disease

MalaCards organs/tissues related to Interstitial Lung Disease:

39
Lung, Testes, Heart, Monocytes, B Cells, Skin, T Cells

Publications for Interstitial Lung Disease

Articles related to Interstitial Lung Disease:

(show top 50) (show all 976)
id Title Authors Year
1
Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency. ( 28254202 )
2017
2
Exercise training improves exercise capacity and quality of life in people with interstitial lung disease [synopsis]. ( 28888691 )
2017
3
Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort. ( 28864644 )
2017
4
Integrative Cardiopulmonary Ultrasound for Interstitial Lung Disease Assessment: Correlation between Lung Ultrasound Performance and Cardiac Involvement. ( 28073593 )
2017
5
Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. ( 28923086 )
2017
6
Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. ( 28704913 )
2017
7
Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab. ( 28891081 )
2017
8
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
9
Interstitial Lung Disease Associated with Adult Niemann-Pick Disease Type B. ( 28601876 )
2017
10
Can we effectively use radiographic imaging and clinical parameters for making an earlier diagnosis of granulomatous interstitial lung disease in patients with common variable immunodeficiency? ( 28477784 )
2017
11
Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency: Methodological issues. ( 28890025 )
2017
12
Common variable immunodeficiency-associated granulomatous and lymphocytic interstitial lung disease successfully treated with a combination regimen of rituximab and azathioprine. ( 28736065 )
2017
13
Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease. ( 28925574 )
2017
14
Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease. ( 28527960 )
2017
15
Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia. ( 28748819 )
2017
16
Concomitant lung cancer and interstitial lung disease: A challenge in clinical practice. ( 28063797 )
2017
17
Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer. ( 28878650 )
2017
18
Respiratory bronchiolitis-associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. ( 28523329 )
2017
19
Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. ( 27995057 )
2017
20
Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck. ( 28741444 )
2017
21
An unusual case of interstitial lung disease in a patient with cardiopulmonary syndrome as the initial presentation of Erdheim-Chester disease. ( 28739622 )
2017
22
FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). ( 27896807 )
2017
23
Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. ( 28915678 )
2017
24
Extracorporeal Membrane Oxygenation for End-Stage Interstitial Lung Disease With Secondary Pulmonary Hypertension at Rest and Exercise: Insights From Simulation Modeling. ( 28863039 )
2017
25
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
26
Dynamic expression of transformating growth factor-I^1 and caveolin-1 in the lung of Bleomycin-induced interstitial lung disease. ( 28932540 )
2017
27
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. ( 27682649 )
2017
28
Extraction of the subpleural lung region from computed tomography images to detect interstitial lung disease. ( 28936704 )
2017
29
Pathologic Separation of Chronic Hypersensitivity Pneumonitis From Fibrotic Connective Tissue Disease-associated Interstitial Lung Disease. ( 28614213 )
2017
30
Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. ( 28842784 )
2017
31
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. ( 28488124 )
2017
32
Interstitial Lung Disease Induced by Pazopanib Treatment. ( 28050004 )
2017
33
Filamin A (FLNA) mutation-A newcomer to the childhood interstitial lung disease (ChILD) classification. ( 28898549 )
2017
34
British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. ( 28351785 )
2017
35
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. ( 28619061 )
2017
36
Interstitial Lung Disease as an Initial Manifestation of Giant Cell Arteritis. ( 28883253 )
2017
37
The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. ( 27309544 )
2017
38
The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. ( 28891101 )
2017
39
Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. ( 28711881 )
2017
40
Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease: A Series of 14 Patients. ( 28926468 )
2017
41
Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. ( 28923440 )
2017
42
Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: aA retrospective analysis. ( 28865463 )
2017
43
Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer. ( 28870955 )
2017
44
Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. ( 28666014 )
2017
45
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. ( 28160477 )
2017
46
Exercise training improves exercise capacity and quality of life in people with interstitial lung disease [commentary]. ( 28888689 )
2017
47
Intravenous Immunoglobulin Monotherapy for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency. ( 28924106 )
2017
48
Interstitial lung disease in systemic sclerosis: current and future treatment. ( 28063071 )
2017
49
Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? ( 28086844 )
2017
50
Patterns of interstitial lung disease and mortality in rheumatoid arthritis. ( 27940586 )
2016

Variations for Interstitial Lung Disease

Expression for Interstitial Lung Disease

Search GEO for disease gene expression data for Interstitial Lung Disease.

Pathways for Interstitial Lung Disease

Pathways related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
2
Show member pathways
13.83 ABCA3 CCL2 CXCL8 IFIH1 MUC1 MUC5B
3
Show member pathways
13.68 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
4
Show member pathways
13.56 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
5
Show member pathways
13.38 CCL2 CCL5 CXCL8 EGFR IL1A IL1B
6
Show member pathways
13.38 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
7
Show member pathways
13.3 CCL17 CCL2 CCL5 CXCL8 EGFR IL1A
8
Show member pathways
12.95 CCL2 CCL5 CXCL8 EDN1 EGFR IL1A
9
Show member pathways
12.87 CCL2 CCL5 CXCL8 IL1B SFTPD TGFB1
10
Show member pathways
12.81 CCL2 CCL5 CXCL8 IFIH1 IL1A IL1B
11
Show member pathways
12.75 CCL5 CXCL8 IFIH1 IL1B TNF
12 12.73 EGFR IL1A IL1B TGFB1 TNF
13
Show member pathways
12.72 EGFR IL1A IL1B TGFB1 TNF
14
Show member pathways
12.62 CCL2 EGFR IL1B ITGA3 TNF
15 12.57 CCL2 CCL5 IFIH1 IL1B TNF
16
Show member pathways
12.3 CCL17 CCL2 CXCL8 IL1B MUC5B TNF
17
Show member pathways
12.29 CXCL8 IL1A IL1B TNF
18
Show member pathways
12.27 IL1A IL1B TGFB1 TNF
19 12.25 IL1A IL1B TGFB1 TNF
20
Show member pathways
12.22 CXCL8 IL1B MUC1 SFTPD TNF
21 12.2 CXCL8 IL1A IL1B TF TNF
22
Show member pathways
12.18 CXCL8 IL1A IL1B TNF
23 12.11 CCL2 EDN1 IL1A IL1B TNF
24 12.07 IL1A IL1B TGFB1 TNF
25
Show member pathways
12.05 CCL17 CCL2 CCL5 CXCL8
26 11.99 CCL2 CXCL8 EGFR IL1A IL1B TGFB1
27 11.98 CXCL8 IL1A IL1B TGFB1
28 11.94 CCL2 CCL5 EDN1 IL1B TNF
29 11.93 IL1A IL1B ITGA3 TNF
30 11.92 CXCL8 IL1B TGFB1 TNF
31 11.92 CCL2 CXCL8 IL1A IL1B MUC1 TGFB1
32 11.8 CXCL8 IL1A IL1B TNF
33 11.77 IL1B TGFB1 TNF
34
Show member pathways
11.7 CXCL8 IL1A IL1B TNF
35 11.7 CCL2 CXCL8 EDN1 IL1A IL1B TGFB1
36 11.61 CXCL8 IL1B TNF
37 11.54 CCL2 IL1B TNF
38 11.54 EGFR IL1B TGFB1 TNF
39 11.52 CCL2 CXCL8 IL1B TGFB1 TNF
40 11.51 IL1A IL1B TNF
41
Show member pathways
11.46 ABCA3 SFTPB SFTPC SFTPD
42 11.45 CCL2 CCL5 CXCL8 IL1A IL1B TGFB1
43 11.44 CCL5 ITGA3 MUC1
44 11.42 CCL2 CCL5 CXCL8 IL1A IL1B TNF
45 11.38 IL1A IL1B TNF
46 11.38 CCL5 IL1A IL1B
47 11.26 IL1A IL1B TGFB1 TNF
48 11.19 CCL5 CXCL8 TNF
49 11.18 CCL17 CCL2 CCL5 CXCL8 IL1A IL1B
50 11.08 CCL2 CCL5 CXCL8 EDN1 IL1B MUC5B

GO Terms for Interstitial Lung Disease

Cellular components related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 CCL17 CCL2 CCL5 CXCL8 EDN1 EGFR
2 endocytic vesicle GO:0030139 9.56 CCL2 EGFR SFTPD TF
3 extracellular space GO:0005615 9.55 ABCA3 CCL17 CCL2 CCL5 CXCL8 EDN1
4 clathrin-coated endocytic vesicle GO:0045334 9.5 SFTPB SFTPC SFTPD
5 multivesicular body lumen GO:0097486 9.4 SFTPB SFTPC
6 alveolar lamellar body GO:0097208 9.37 ABCA3 SFTPB
7 lamellar body GO:0042599 9.33 SFTPB SFTPC SFTPD

Biological processes related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.99 EGFR IL1B TGFB1 TNF
2 chemotaxis GO:0006935 9.99 CCL17 CCL2 CCL5 CXCL8
3 MAPK cascade GO:0000165 9.97 CCL2 CCL5 EGFR IL1B TGFB1 TNF
4 animal organ morphogenesis GO:0009887 9.94 CCL2 NKX2-1 SFTPB TNF
5 cellular response to mechanical stimulus GO:0071260 9.9 EGFR IL1B TGFB1
6 response to glucocorticoid GO:0051384 9.89 ABCA3 CCL2 TNF
7 regulation of insulin secretion GO:0050796 9.89 CCL5 IL1B TNF
8 positive regulation of epithelial cell proliferation GO:0050679 9.89 CCL5 EGFR TGFB1
9 positive regulation of cell migration GO:0030335 9.89 CCL5 EDN1 EGFR TGFB1
10 chemokine-mediated signaling pathway GO:0070098 9.88 CCL17 CCL2 CCL5 CXCL8
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 CCL17 CCL2 CCL5 EGFR TGFB1 TNF
12 positive regulation of cell adhesion GO:0045785 9.87 CCL2 CCL5 TNF
13 cellular response to drug GO:0035690 9.87 CCL2 EDN1 EGFR IL1B
14 positive regulation of interleukin-6 production GO:0032755 9.86 IL1A IL1B TNF
15 positive regulation of cell division GO:0051781 9.86 IL1A IL1B TGFB1
16 cellular response to interferon-gamma GO:0071346 9.86 CCL17 CCL2 CCL5 EDN1
17 inflammatory response GO:0006954 9.86 CCL17 CCL2 CCL5 CXCL8 IL1A IL1B
18 monocyte chemotaxis GO:0002548 9.85 CCL17 CCL2 CCL5
19 positive regulation of MAP kinase activity GO:0043406 9.85 EDN1 EGFR TGFB1 TNF
20 cellular response to tumor necrosis factor GO:0071356 9.85 CCL17 CCL2 CCL5 CXCL8 EDN1
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 IL1A IL1B TNF
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 CCL5 EDN1 EGFR TNF
23 cellular response to dexamethasone stimulus GO:0071549 9.82 CCL2 EGFR TGFB1
24 negative regulation of mitotic cell cycle GO:0045930 9.81 EGFR TGFB1 TNF
25 cellular response to fibroblast growth factor stimulus GO:0044344 9.8 CCL2 CCL5 CXCL8
26 positive regulation of phagocytosis GO:0050766 9.8 IL1B SFTPD TNF
27 positive regulation of vascular endothelial growth factor production GO:0010575 9.79 IL1A IL1B TGFB1
28 positive regulation of mitotic nuclear division GO:0045840 9.79 EDN1 IL1A IL1B
29 negative regulation of myoblast differentiation GO:0045662 9.78 CCL17 TGFB1 TNF
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 EDN1 EGFR IL1B TNF
31 cellular response to organic cyclic compound GO:0071407 9.77 CCL2 CCL5 IL1B TGFB1 TNF
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL1B TNF
33 positive regulation of superoxide anion generation GO:0032930 9.74 EGFR TGFB1
34 PERK-mediated unfolded protein response GO:0036499 9.74 CCL2 CXCL8
35 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.73 IL1A IL1B
36 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.73 CCL5 CXCL8
37 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 TGFB1 TNF
38 cerebral cortex cell migration GO:0021795 9.73 EGFR NKX2-1
39 salivary gland morphogenesis GO:0007435 9.73 EGFR TGFB1
40 respiratory gaseous exchange GO:0007585 9.73 EDN1 SFTPB SFTPC SFTPD
41 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
42 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.72 IL1A IL1B
43 cellular response to interleukin-1 GO:0071347 9.72 CCL17 CCL2 CCL5 CXCL8 EDN1
44 maternal process involved in parturition GO:0060137 9.71 CCL2 EDN1
45 neutrophil activation GO:0042119 9.71 CCL5 CXCL8
46 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 EGFR TGFB1
47 ectopic germ cell programmed cell death GO:0035234 9.71 IL1A IL1B
48 macrophage chemotaxis GO:0048246 9.71 CCL2 CCL5 SFTPD
49 positive regulation of prostaglandin secretion GO:0032308 9.7 EDN1 IL1B
50 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF

Molecular functions related to Interstitial Lung Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 CCL17 CCL2 CCL5 CXCL8 EDN1 IL1A
2 chemokine activity GO:0008009 9.26 CCL17 CCL2 CCL5 CXCL8
3 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5

Sources for Interstitial Lung Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....